GeoVax to Report Third Quarter 2024 Financial Results
GeoVax Labs, Inc. (NASDAQ: GOVX), a pioneering biotechnology company, is poised to announce its financial results for the third quarter of 2024. This announcement is scheduled for a date after the close of U.S. markets. Following this release, the company’s management team will engage with participants through a live conference call.
Conference Call Information
On the day of the financial report, GeoVax will host a live conference call at 4:30 PM ET. This session aims to provide stakeholders with an insightful corporate update and a thorough discussion regarding the financial outcomes. Participants interested in accessing the call can register beforehand to receive the necessary details for joining the session.
Overview of GeoVax Labs
GeoVax Labs is at the forefront of developing vital immunotherapies and vaccines targeting some of the globe's most concerning infectious diseases and various types of cancers. Their flagship clinical program, named GEO-CM04S1, focuses on offering an innovative COVID-19 vaccine. Recently, the company secured a contract with BARDA, allowing it to proceed with an extensive Phase 2b clinical trial involving 10,000 participants to assess the effectiveness of GEO-CM04S1 against an established COVID-19 vaccine.
Innovations in Vaccine Development
This COVID-19 vaccine is participating in three active Phase 2 clinical trials. These trials explore its potential as a primary vaccine for immunocompromised individuals—such as those with serious hematologic conditions—as well as a booster for patients with chronic lymphocytic leukemia (CLL). Furthermore, there’s significant interest in GEO-CM04S1’s role as a durable booster for healthy individuals who have already received the mRNA vaccines.
Oncology Advances with Gedeptin®
In the realm of oncology, GeoVax is making strides with its oncolytic solid tumor therapy, Gedeptin®. The company recently completed a multicenter Phase 1/2 clinical trial focusing on advanced head and neck cancers. An exciting next step in their clinical journey includes a planned Phase 2 trial that will combine Gedeptin® with an immune checkpoint inhibitor, targeting first recurrent head and neck cancer. This trial is expected to initiate in the first half of 2025.
A Focus on Intellectual Property
GeoVax prides itself on its robust intellectual property portfolio that supports its innovative technologies and product candidates. The company holds worldwide rights for its products, providing a solid foundation for its ongoing and future endeavors in the biotechnology field.
Leadership and Commitment to Growth
The leadership team at GeoVax comprises seasoned professionals with a history of creating significant value across various life science firms. Their expertise and vision for advancing healthcare solutions play a crucial role in the company’s ongoing success and ambitions.
Future Directions for GeoVax
As they move forward, GeoVax continues to focus on enhancing the efficacy of its therapeutic products and vaccines. With their commitment to innovation and patient care, they work tirelessly to address critical health challenges faced by populations worldwide. For further updates, stakeholders are encouraged to visit the GeoVax website.
Frequently Asked Questions
When will GeoVax report its Q3 2024 financial results?
GeoVax will report its Q3 2024 financial results after the close of U.S. markets on the scheduled date.
How can I participate in the conference call?
Participants can register online to receive the details needed for joining the conference call.
What is GEO-CM04S1?
GEO-CM04S1 is GeoVax's next-generation COVID-19 vaccine undergoing extensive testing in clinical trials.
What types of trials is GeoVax conducting?
GeoVax is conducting several Phase 2 clinical trials for its COVID-19 vaccine and Gedeptin® cancer therapy, aimed at various patient populations.
Who can be contacted for more information?
For inquiries, individuals can reach out to the provided media or investor relations contacts via their respective email addresses.
